Search clinical trials for: REGN7508 (IV)

Total 3221 results

Regeneron Pharmaceuticals

Recruiting

A Trial to Learn if Single Ascending Intravenous (IV) Doses of REGN7508 Are Safe and Well Tolerated, and How it Works in the Body of Healthy Adult Participants

Healthy Volunteer

United Kingdom
Regeneron Pharmaceuticals

Completed

Study of REGN1500 in Participants With Homozygous Familial Hypercholesterolemia (HoFH)

Homozygous Familial Hypercholesterolemia

United States, Netherlands, Canada
Regeneron Pharmaceuticals

Not yet recruiting

A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC) (ROXI-CATH)

Venous Thromboembolism
Regeneron Pharmaceuticals
Sanofi

Terminated

Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis

United States, Hungary, Korea, Republic of, Germany, Japan, Poland, Australia, Canada, Czechia, Spain, United Kingdom
Regeneron Pharmaceuticals
Sanofi

Completed

A Study of Intravenously or Subcutaneously Administered REGN3500 in Healthy Adult Subjects

Healthy Volunteers

Belgium
Regeneron Pharmaceuticals
Sanofi

Completed

Study of Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of REGN3500 in Adults With Moderate Asthma

Asthma | Moderate Asthma

United Kingdom
Regeneron Pharmaceuticals

Completed

Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia

Homozygous Familial Hypercholesterolemia

United States, Netherlands, Australia, Austria, Canada, France, Greece, Italy, Japan, South Africa, Ukraine
Regeneron Pharmaceuticals

Completed

Single Ascending-dose Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Participants

Allergy

United Kingdom, New Zealand, Netherlands, Sweden
Regeneron Pharmaceuticals

Completed

Study of Evinacumab (REGN1500) in Caucasian and in Japanese Healthy Volunteers

Healthy Volunteers

United States
Regeneron Pharmaceuticals
Sanofi

Completed

Ascending Dose Study of the Safety and Tolerability of REGN728 in Healthy Volunteers

Healthy

United States
Regeneron Pharmaceuticals

Completed

Study in Cat-Allergic Patients With Asthma to Evaluate the Efficacy of a Single Dose of REGN1908-1909 to Reduce Bronchoconstriction Upon Cat Allergen Challenge

Cat Allergy | Mild Asthma

France
Regeneron Pharmaceuticals

Completed

Study to Assess the Safety and Tolerability of Single Doses of REGN1500

Hypertriglyceridemia

United States
Regeneron Pharmaceuticals

Completed

Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1500

Metabolic Disorders

United States
Regeneron Pharmaceuticals

Terminated

Efficacy and Safety of Evinacumab in Adult Patients With Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis

Hypertriglyceridemia

United States, Germany, Netherlands, Canada
Regeneron Pharmaceuticals

Completed

Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia

Homozygous Familial Hypercholesterolemia

United States, Netherlands, South Africa, Australia, Austria, Canada, Czechia, France, Greece, Italy, Japan, Ukraine
Regeneron Pharmaceuticals

Completed

Safety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis

Severe Hypertriglyceridemia (sHTG)

United States, Canada, Italy, United Kingdom
Regeneron Pharmaceuticals

Completed

Single Ascending-dose Study of the Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Subjects

Allergy

United States
Regeneron Pharmaceuticals

Completed

Evaluate the Efficacy and Safety of Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterolemia

Homozygous Familial Hypercholesterolemia

United States, Australia, Austria, Netherlands, Taiwan, Ukraine
Regeneron Pharmaceuticals
Sanofi

Terminated

Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis

United States, Korea, Republic of, Belgium, Czechia, Germany, Poland, Spain
Regeneron Pharmaceuticals

Terminated

A Study to Examine the Efficacy and Safety of Anti-Fel d 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic Rhinitis Who Live With a Cat

Allergic Rhinitis Due to Cat Allergy

United States, Belgium, Germany, Poland, Canada, France
Sanofi
Regeneron Pharmaceuticals

Recruiting

Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) (AERIFY-2)

Chronic Obstructive Pulmonary Disease

Korea, Republic of, Turkey, United States, Chile, Czechia, Israel, Russian Federation, Argentina, Brazil, Bulgaria, Canada, Denmark, Estonia, France, Georgia, Germany, Hungary, India, Japan, Latvia, Lithuania, Mexico, Netherlands, Norway and more
Sanofi
Regeneron Pharmaceuticals

Recruiting

Mechanistic Study of the Effect of Itepekimab on Airway Inflammation in Patients With COPD (AERIFY-3)

Chronic Obstructive Pulmonary Disease

United States, Netherlands, Belgium, Denmark, Germany, United Kingdom, Brazil
Regeneron Pharmaceuticals

Active, not recruiting

A Trial to Learn if Different Doses of REGN7544 Are Safe in Healthy Adult Participants

Healthy Volunteers

New Zealand
Sanofi
Regeneron Pharmaceuticals

Recruiting

Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) (AERIFY-1)

Chronic Obstructive Pulmonary Disease

Bulgaria, China, United States, Argentina, Chile, Czechia, Georgia, Greece, Hungary, India, Israel, Italy, Mexico, Poland, Romania, Russian Federation, Slovakia, Taiwan, Ukraine, United Kingdom, Mauritius
Sanofi
Regeneron Pharmaceuticals

Recruiting

A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis

Bronchiectasis

United Kingdom, Japan, United States, Israel, Canada
Sanofi
Regeneron Pharmaceuticals

Recruiting

A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD (AERIFY-4)

Chronic Obstructive Pulmonary Disease

United States, China, Hungary, Israel, Poland, Taiwan, Canada, Chile, Korea, Republic of, Japan
Taipei City Hospital

Not yet recruiting

TCHCCT-Zhong-Xing-Emergency-Department Ultrasound With IV Contrast in Acute Flank Pain

Acute Flank Pain

Taiwan
Eli Lilly and Company

Completed

A Study of LY3316531 in Healthy Participants and in Participants With Psoriasis

Psoriasis

United States
Healthgen Biotechnology Corp.

Recruiting

Study of OsrhAAT or Placebo in Healthy Volunteers

Emphysema Secondary to Congenital AATD

United States
Kyowa Kirin Co., Ltd.

Terminated

Study of KHK 4323 in Healthy Volunteers and Subjects With Atopic Dermatitis

Atopic Dermatitis

Japan
Healthgen Biotechnology Corp.

Completed

A Study of OsrHSA in Adult Healthy Male and Female Volunteers

Ascites Hepatic

United States
Eli Lilly and Company

Completed

A Study of LY3002813 in Participants With Alzheimer's Disease

Alzheimer Disease

United States, Japan
Asir John Samuel
Maharishi Markendeswar University (Deemed to be University)

Recruiting

Class IV Laser Therapy on Ejection Fraction, Cardio Biomarkers and Functional Outcomes

Acute Coronary Syndrome

India
Regeneron Pharmaceuticals

Completed

Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia

Hypercholesterolemia

United States, Spain, Australia, Netherlands, Japan, Jordan, Denmark, Israel, Sweden, South Africa, Canada, Austria, Czechia, France, Italy, New Zealand, Norway, Poland, Russian Federation, United Kingdom
GlaxoSmithKline

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Oral and Intravenous GSK1322322 in Healthy Subjects

Infections, Bacterial

United States
Wockhardt

Completed

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of Intravenous WCK 771

Bioavailability

United States
C. R. Bard

Completed

AccuCath Guidewire Intravenous (IV) Device Versus Conventional IV Catheter In General Nursing Use

Vascular Access Complication

United States
Prometheus Biosciences, Inc., a subsidiary of Merck...
Altasciences Company Inc.

Completed

Bioavailability of SC Formulation and Japanese Ethnobridging Study for PRA023

Healthy

United States
Eli Lilly and Company

Completed

A Study of LY3475766 in Healthy Participants

Dyslipidemias

United States
Oculis
Neurotrials

Recruiting

OCS-05 in Patients With Acute Optic Neuritis (ACUITY)

Optic Neuritis | Optic; Neuritis, With Demyelination

France
Flame Biosciences

Withdrawn

Phase 1/2a Study to Evaluate FL-301 in Patients With Advanced Solid Tumors

Gastric Cancer | Solid Tumor | Pancreas Cancer
Gmax Biopharm LLC.

Recruiting

A Study of GMA301 in Subjects With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

United States, China
Qilu Pharmaceutical Co., Ltd.

Completed

Safety, Tolerability, Pharmacokinetics of Intravenous FL058 and Meropenem in Healthy Subjects(SAD/MAD)

Healthy

China
Bayer

Recruiting

A Study to Learn How Safe the Study Treatment BAY2701250 is, How it Affects the Body and How it Moves Into, Through and Out of the Body in Healthy Male Participants When a Single Amount is Given as an Injection Into the Vein (Intravenous Infusion) or Under the Skin (Subcutaneous Injection)

Pulmonary Hypertension Due to Left Heart Disease

Germany
Alexion Pharmaceuticals, Inc.
Syneos Health

Completed

Study of ALXN1820 in Healthy Adult Participants

Healthy

Australia, United Kingdom
Eli Lilly and Company

Completed

A Safety Study of LY3462817 in Healthy Japanese and Non-Japanese Participants

Healthy

United States
Eli Lilly and Company

Completed

A Study of LY3361237 in Healthy Participants

Healthy

United States
Universitaire Ziekenhuizen KU Leuven
BEDAL; Remedus

Terminated

Impact of Availability of Showerpatch for Patients With Intravenous Catheters (ISIC)

Neoplasms | Cystic Fibrosis | Pulmonary Hypertension

Belgium
William Beaumont Hospitals

Completed

Peripheral Intravenous Catheter Securement With Tissue Adhesive

Vascular Access Devices

United States
Eli Lilly and Company

Terminated

A Study of LY3478006 in Healthy Participants

Healthy

United States

Search clinical trials for: REGN7508 (IV)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Taiwan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations